RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals ROA 2025

Mirum Pharmaceuticals ROA

-0.25

Ticker

MIRM

ISIN

US6047491013

WKN

A2PM29

In 2025, Mirum Pharmaceuticals's return on assets (ROA) was -0.25, a -34.26% increase from the -0.38 ROA in the previous year.

Mirum Pharmaceuticals Aktienanalyse

What does Mirum Pharmaceuticals do?

Mirum Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and marketing of therapeutics for rare intestinal diseases. The company was founded in 2018 in California, USA and has experienced rapid growth since then. The company was founded after an unusual event in 2015 when Shire Pharmaceuticals plc, a large British pharmaceutical company, acquired the biotech company Lumena Pharmaceuticals Inc. The management of Lumena discovered a compound that they believed could relieve cholestasis, a condition where bile cannot flow adequately and therefore remains in the liver. They realized that this compound, if modified and used in a new formulation, could also be used to treat other rare intestinal diseases. The management of Lumena decided to pursue this idea and thus founded Mirum Pharmaceuticals Inc. The company's business model is to develop novel medications for the treatment of severe and rare intestinal diseases through a combination of in-house research and external collaborations. Mirum Pharmaceuticals Inc aims to fill a niche focusing on smaller patient populations that are often overlooked by larger pharmaceutical companies due to their rarity. The company also aims to work closely with patients and their families to ensure that their needs and concerns are incorporated into their product development processes. Currently, Mirum Pharmaceuticals Inc's research and development efforts focus on two main areas: cholestasis and intestinal enteropathies. Cholestasis is a condition where the liver is unable to secrete bile into the intestine, resulting in the accumulation of bile in the body and damage to liver cells and other organs. Mirum Pharmaceuticals Inc is currently developing Maralixibat, a medication targeting the treatment of intrahepatic cholestasis in children. Intestinal enteropathies are rare intestinal diseases characterized by a disruption of the intestinal tract. Mirum Pharmaceuticals Inc is dedicated to researching and developing a medication for the treatment of PFIC, a rare condition where bile fluid is no longer adequately excreted. In this regard, the company has entered into an agreement with Dova Pharmaceuticals Inc., which was acquired by Merck&Co. in mid-2019. Under this agreement, Mirum Pharmaceuticals Inc acquired the rights to a medication for the treatment of PFIC developed by Dova. Mirum Pharmaceuticals solutions aim to treat patients on a relevant basis and provide support for families and caregivers of patients. In summary, Mirum Pharmaceuticals Inc is a biopharmaceutical company that emerged from a spin-out of Lumena Pharmaceuticals Inc from Shire. It has focused on the development of therapeutics for rare intestinal diseases and works closely with patients and their families to ensure their concerns are considered in product development processes. The product research of Mirum Pharmaceuticals Inc currently focuses on Maralixibat, a medication for the treatment of intrahepatic cholestasis, as well as Mirum Pharmaceuticals Inc, a medication for the treatment of PFIC. Mirum Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Mirum Pharmaceuticals's Return on Assets (ROA)

Mirum Pharmaceuticals's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Mirum Pharmaceuticals's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Mirum Pharmaceuticals's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Mirum Pharmaceuticals’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Mirum Pharmaceuticals stock

What is the Return on Assets (ROA) of Mirum Pharmaceuticals this year?

The Return on Assets (ROA) of Mirum Pharmaceuticals is -0.25 undefined this year.

What was the ROA of Mirum Pharmaceuticals compared to the previous year?

The ROA of Mirum Pharmaceuticals has increased by -34.26% compared to the previous year.

What consequences do high ROA have for investors of Mirum Pharmaceuticals?

A high ROA is advantageous for investors of Mirum Pharmaceuticals, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Mirum Pharmaceuticals?

A low ROA can be unfavorable for investors of Mirum Pharmaceuticals as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Mirum Pharmaceuticals affect the company?

An increase in ROA of Mirum Pharmaceuticals can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Mirum Pharmaceuticals impact the company?

A reduction in the ROA of Mirum Pharmaceuticals can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Mirum Pharmaceuticals?

Some factors that can influence the ROA of Mirum Pharmaceuticals include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Mirum Pharmaceuticals important for investors?

The ROA of Mirum Pharmaceuticals is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Mirum Pharmaceuticals take to improve ROA?

To improve ROA, Mirum Pharmaceuticals can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Mirum Pharmaceuticals pay?

Over the past 12 months, Mirum Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirum Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirum Pharmaceuticals?

The current dividend yield of Mirum Pharmaceuticals is .

When does Mirum Pharmaceuticals pay dividends?

Mirum Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirum Pharmaceuticals?

Mirum Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Mirum Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirum Pharmaceuticals located?

Mirum Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirum Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirum Pharmaceuticals from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.

When did Mirum Pharmaceuticals pay the last dividend?

The last dividend was paid out on 1/15/2025.

What was the dividend of Mirum Pharmaceuticals in the year 2024?

In the year 2024, Mirum Pharmaceuticals distributed 0 USD as dividends.

In which currency does Mirum Pharmaceuticals pay out the dividend?

The dividends of Mirum Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mirum Pharmaceuticals

Our stock analysis for Mirum Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mirum Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.